lenalidomide

Known as: 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione, 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-, IMid-1 
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2005
Highly Cited
2005
We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirty… (More)
  • table 2
  • table 3
  • table 1
Is this relevant?